Articles related to GENITOURINARY CANCER
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.
Oncology, Medical November 13th 2023
Report From ASCO 2023: Centering on the Patient and Focusing on GU Cancers
Delve into key insights from ASCO 2023, which emphasized patient-centered care in genitourinary oncology, including the efficacy of virtual prostate cancer clinics and the critical need for initiating serious-illness conversations.
Hematology/Oncology August 29th 2023
Systemic Therapy for Nonmetastatic Castration-Resistant Prostate Cancer
Second-generation androgen receptor pathway inhibitors (ARPIs) have proven to be essential in managing nonmetastatic castration-resistant prostate cancer (nmCRPC). These treatments provide hope in delaying metastasis and improving overall survival, significantly altering the disease’s prognosis.
Oncology, Medical July 18th 2023
FDA Approves Enfortumab Vedotin Combo for Advanced Urothelial Carcinoma
The decision was based on the findings of the open-label, multi-cohort, multicenter, phase 1b/2 clinical trial EV-103/KEYNOTE-869. Patients who participated in the study and were included in the current analysis had locally advanced or metastatic disease, were ineligible for cisplatin-containing chemotherapy, and had not previously received systemic therapy. The primary efficacy outcome measures for the study were the objective response rate (ORR) and duration of response (DoR), which were determined by an independent central review using RECIST v1.1. The ORR for the 121 patients treated with the combination was 68%, with 12% having a complete response. The median DoR for dose escalation was 22 months for two cohorts but not for a third.
Oncology, Medical April 10th 2023
Association of Prostate-Specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities
In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.
Oncology, Medical October 31st 2022